Point-of-care test system for detection of immunoglobulin-G and -M against nucleocapsid protein and spike glycoprotein of SARS-CoV-2

Peng, Tao; Sui, Zhiwei; Huang, Zhenghui; Xie, Jun; Wen, Kai; Zhang, Yongzhuo; Huang, Wenfeng; Mi, Wei; Peng, Ke; Dai, Xinhua; Fang, Xiang

doi:10.1016/j.snb.2020.129415

Cited by 39 publications

(28 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A rapid and simple method to simultaneously detect IgG and IgM antibodies against the SARS‐CoV‐2 virus was developed, which can discriminate COVID‐19 patients from healthy individuals in 15 min and can identify patients at different infection stages 43 . Tao Peng et al have developed a detection method for quantification of IgG and IgM against SARS‐CoV‐2 44 …”

Section: Methodsmentioning

confidence: 99%

Coronavirus Disease 2019 (COVID‐19): Emerging detection technologies and auxiliary analysis

Chen

Huang

Zhou

et al. 2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

The ongoing COVID‐19 pandemic constitutes a new challenge for public health. Prevention and control of infection have become urgent and serious issues. To meet the clinical demand for higher accuracy of COVID‐19 detection, the development of fast and efficient methods represents an important step. The most common methods of COVID‐19 diagnosis, relying on real‐time fluorescent quantitative PCR(RT‐qPCR), computed tomography, and new‐generation sequencing technologies, have a series of advantages, especially for early diagnosis and screening. In addition, joint efforts of researchers all over the world have led to the development of other rapid detection methods with high sensitivity, ease of use, cost‐effectiveness, or allowing multiplex analysis based on technologies such as dPCR, ELISA, fluorescence immunochromatography assay, and the microfluidic detection chip method. The main goal of this review was to provide a critical discussion on the development and application of these different analytical methods, which based on etiology, serology, and molecular biology, as well as to compare their respective advantages and disadvantages. In addition to these methods, hematology and biochemistry, as well as auxiliary analysis based on pathological anatomy, ultrasonography, and cytokine detection, will help understand COVID‐19 pathogenesis. Together, these technologies may promote and open new windows to unravel issues surrounding symptomatic and asymptomatic COVID‐19 infections and improve clinical strategies toward reducing mortality.

show abstract

Section: Methodsmentioning

confidence: 99%

Coronavirus Disease 2019 (COVID‐19): Emerging detection technologies and auxiliary analysis

Chen

Huang

Zhou

et al. 2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“… Detected Virus Detected analyte Reporter probe Capture probe Control Probe Sensitivity LOD Ref. SARS-CoV-2 Spike protein Au NPs SARS-COV-2, S1 spike protein 2,3′-sialyl lactose-BSA - 5 μg [ 45 ] SARS-CoV-2 Anti-SARS-CoV-2 IgM Au NPs SARS-CoV-2 NP Anti-mouse IgG 100% - [ 46 ] SARS-CoV-2 RNA Au NPs Anti-FITC Ab Biotin 100% - [ 47 ] SARS-CoV-2 Nucleoprotein Ag Cellulose nanobead Nucleoprotein Ag Anti-human IgG antibodies - 2 ng [ 48 ] SARS CoV-2 Anti-SARS-CoV-2 IgM- IgG - IgM Au-NPs Protein A & nucleocapsid proteins Avidin 94.6% - [ 49 ] SARS CoV-2 Anti-SARS-CoV-2 IgA Au-NPs Nucleocapsid antigen staphylococcal protein A - - [ 50 ] SARS CoV-2 Anti-SARS-CoV-2 IgG Au-NPs SARS CoV-2 Anti-mouse IgG 69.1% - [ 51 ] SARS CoV-2 Nucleoprotein and spike protein Au-NPs Mouse anti-human IgG and anti-human IgM mouse anti-tylosin antibody 96% - [ 52 ] IAV Nucleoprotein Ag Au/Pt NPs conjugated with anti-Influenza A NP …”

Section: Viral Infections Determination Using Lfa Sensing Platformsmentioning

confidence: 99%

Lateral flow assays (LFA) as an alternative medical diagnosis method for detection of virus species: The intertwine of nanotechnology with sensing strategies

Sadeghi

Sohrabi

Hejazi

et al. 2021

TrAC Trends in Analytical Chemistry

View full text Add to dashboard Cite

“…Self-testing for COVID-19 using immunochromatographic assays, also known as lateral flow assays, is widespread. Common rapid serological tests that detect SARS-CoV-2 antibody levels in circulation usually employ gold nanoparticle- or fluorescent reporter-labeled recombinant SARS-CoV-2 antigen and anti-human immunoglobulin coated test lines ( Liu et al, 2021 ; Peng et al, 2021 ). Other rapid methods that involve the labeling of anti-human immunoglobulins and recombinant SARS-CoV-2 antigen coating in test lines have been developed ( Chen et al, 2020 ; Roda et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Dual-detection fluorescent immunochromatographic assay for quantitative detection of SARS-CoV-2 spike RBD-ACE2 blocking neutralizing antibody

Duan¹,

Shi

Zhang³

et al. 2022

Biosensors and Bioelectronics

View full text Add to dashboard Cite

The global effort against the COVID-19 pandemic dictates that routine quantitative detection of SARS-CoV-2 neutralizing antibodies is vital for assessing immunity following periodic revaccination against new viral variants. Here, we report a dual-detection fluorescent immunochromatographic assay (DFIA), with a built-in self-calibration process, that enables rapid quantitative detection of neutralizing antibodies that block binding between the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein and the angiotensin-converting enzyme 2 (ACE2). Thus, this assay is based on the inhibition of binding between ACE2 and the RBD of the SARS-CoV-2 spike protein by neutralizing antibodies, and the affinity of anti-human immunoglobulins for these neutralizing antibodies. Our self-calibrating DFIA shows improved precision and sensitivity with a wider dynamic linear range, due to the incorporation of a ratiometric algorithm of two-reverse linkage signals responding to an analyte. This was evident by the fact that no positive results (0/14) were observed in verified negative samples, while 22 positives were detected in 23 samples from verified convalescent plasma. A comparative analysis of the ability to detect neutralizing antibodies in 266 clinical serum samples including those from vaccine recipients, indicated that the overall percent agreement between DFIA and the commercial ELISA kit was 90.98%. Thus, the proposed DFIA provides a more reliable and accurate rapid test for detecting SARS-CoV-2 infections and vaccinations in the community. Therefore, the DFIA based strategy for detecting biomarkers, which uses a ratiometric algorithm based on affinity and inhibition reactions, may be applied to improve the performance of immunochromatographic assays.

show abstract

Point-of-care test system for detection of immunoglobulin-G and -M against nucleocapsid protein and spike glycoprotein of SARS-CoV-2

Cited by 39 publications

References 26 publications

Coronavirus Disease 2019 (COVID‐19): Emerging detection technologies and auxiliary analysis

Coronavirus Disease 2019 (COVID‐19): Emerging detection technologies and auxiliary analysis

Lateral flow assays (LFA) as an alternative medical diagnosis method for detection of virus species: The intertwine of nanotechnology with sensing strategies

Dual-detection fluorescent immunochromatographic assay for quantitative detection of SARS-CoV-2 spike RBD-ACE2 blocking neutralizing antibody

Contact Info

Product

Resources

About